Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO John Todd Koning Sells 37,500 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO John Todd Koning sold 37,500 shares of the stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $12.82, for a total transaction of $480,750.00. Following the completion of the sale, the chief financial officer now directly owns 393,356 shares in the company, valued at $5,042,823.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

John Todd Koning also recently made the following trade(s):

• On Friday, March 1st, John Todd Koning sold 121,601 shares of Alphatec stock. The stock was sold at an average price of $13.30, for a total transaction of $1,617,293.30.

Alphatec Trading Up 1.6 %

NASDAQ ATEC opened at $12.44 on Friday. The company has a fifty day simple moving average of $13.69 and a two-hundred day simple moving average of $13.46. The stock has a market cap of $1.72 billion, a P/E ratio of -8.03 and a beta of 1.55. Alphatec Holdings, Inc. has a 12-month low of $8.66 and a 12-month high of $19.14. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 6.54.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.09). The business had revenue of $138.00 million for the quarter, compared to analyst estimates of $131.90 million. The company’s revenue was up 30.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.33) earnings per share. On average, analysts forecast that Alphatec Holdings, Inc. will post -1.1 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC raised its holdings in shares of Alphatec by 97.0% during the fourth quarter. First Light Asset Management LLC now owns 5,976,851 shares of the medical technology company’s stock worth $90,310,000 after purchasing an additional 2,943,310 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Alphatec by 1.8% during the third quarter. Vanguard Group Inc. now owns 4,615,223 shares of the medical technology company’s stock worth $59,859,000 after purchasing an additional 80,101 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Alphatec by 24.5% during the third quarter. American Century Companies Inc. now owns 2,655,328 shares of the medical technology company’s stock worth $34,440,000 after purchasing an additional 523,323 shares during the last quarter. Fred Alger Management LLC raised its holdings in shares of Alphatec by 48.9% during the third quarter. Fred Alger Management LLC now owns 2,336,718 shares of the medical technology company’s stock worth $30,307,000 after purchasing an additional 767,280 shares during the last quarter. Finally, Cerity Partners LLC purchased a new position in shares of Alphatec during the fourth quarter worth $28,451,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wells Fargo & Company assumed coverage on shares of Alphatec in a research note on Friday, February 9th. They issued an “overweight” rating and a $26.00 target price on the stock. Needham & Company LLC increased their price objective on shares of Alphatec from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Monday, March 4th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $25.00 price objective on shares of Alphatec in a research note on Wednesday, March 20th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Alphatec currently has an average rating of “Moderate Buy” and an average target price of $23.63.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.